Action AZN ASTRAZENECA PLC
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués AstraZeneca PLC

Actions

AZN

GB0009895292

Marché Fermé - London S.E.
Autres places de cotation
 17:35:06 21/06/2024 		Varia. 5j. Varia. 1 janv.
12 472 GBX +0,60% Graphique intraday de AstraZeneca PLC -0,30% +17,66%
21/06 La FDA américaine approuve le médicament de Roche pour un trouble sanguin chronique RE
21/06 Les actions européennes négociées aux États-Unis sous forme de certificats de dépôt américains sont orientées à la baisse vendredi, mais terminent la semaine en hausse MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Astrazeneca - Update on the CAPItello-290 Phase III trial for Truqap plus chemotherapy in advanced or metastatic triple-negative breast cancer
AQ
Squamous Cell Carcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA | Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna
AQ
AstraZeneca - IMFINZI plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
AQ
AstraZeneca : Update on CAPItello-290 Phase III trial
PU
Astrazeneca - Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
AQ
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
BU
AstraZeneca : Imfinzi plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer Form 6 K
PU
AstraZeneca : Imfinzi approved in the US for endometrial cancer
PU
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
BU
AstraZeneca : Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
PU
AstraZeneca - Farxiga approved in the US for the treatment of paediatric type-2 diabetes
AQ
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
BU
AstraZeneca : Transaction by Person Discharging Managerial Responsibilities Form 6 K
PU
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development (CRDL,JAZZ, NVO, AZN, SNY)
AQ
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development
AQ
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
BU
Cereno Scientific moves to new office space at GoCo Health Innovation City in Gothenburg
AQ
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
AQ
Pharma Company Astrazeneca Withdrawing Covid Vaccine Because It's Outdated - Not 'After Admitting to Dangerous Side Effect'
AQ
Astrazeneca completes £1.5bn Fusion Pharmaceuticals deal
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action AZN
  4. Actualités AstraZeneca PLC
  5. Communiqués